Biovica launches DiviTum TKa for patients with early breast cancer undergoing adjuvant treatment. The test is provided as a Laboratory Developed Test (LDT) from the company's CLIA-certified laboratory in the US. The launch opens a new market indication that fivefolds the addressable market for DiviTum TKa, corresponding to approximately USD 3 billion annually in key markets. The test enables early identification of treatment response in HR+ patients treated with CDK4/6 inhibitors.
- We are very proud to offer DiviTum TKa for use in early breast cancer in patients undergoing adjuvant treatment. This marks the beginning of a new phase in our commercialization with significantly increased market potential and the opportunity to improve treatment for an even larger number of patients., says Anders Rylander, CEO of Biovica.
